Nabiximols

Department of Health and Social Care written question – answered on 25th October 2021.

Alert me about debates like this

Photo of Margaret Hodge Margaret Hodge Labour, Barking

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle the geographical differences that exist across England in the prescription of Sativex, which is used to treat moderate to severe spasticity in MS.

Photo of Margaret Hodge Margaret Hodge Labour, Barking

To ask the Secretary of State for Health and Social Care, what steps his Department has taken to help encourage prescriptions of Sativex on the NHS in England, following the recommendation of NICE on the use of that drug for patients with MS.

Photo of Edward Argar Edward Argar Minister of State (Department of Health and Social Care)

The latest guidelines from the National Institute for Health and Care Excellence’s (NICE) recommend Sativex to treat moderate to severe spasticity in adults with multiple sclerosis, if other pharmacological treatments for spasticity are not effective. The decision on whether to prescribe must be taken by a specialist clinician on a case by case basis and funding of this medicine is subject to local National Health Service decisions. On 6 September, NHS England issued a reminder to clinical commissioning groups of the NICE guidance relating to Sativex and their responsibilities and will be monitoring uptake.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.